Tick-borne red meat allergy (α -gal syndrome)

Samira Jeimy MD PhD, Rongbo Zhu MD

Cite as: CMAJ 2023 October 3;195:E1305-6. doi: 10.1503/cmaj.231067

1 Tick-borne red meat allergy occurs from sensitization to a carbohydrate, galactose-α-1,3-galactose (α-gal)

The lone star tick (*Amblyomma americanum*) is commonly found in the southern United States, but its prevalence in Canada is increasing.¹ The tick's saliva contains a high level of α -gal, a carbohydrate antigen also present in nonprimate mammalian cell membranes.² Skin and blood-stream exposure to this antigen through a tick bite leads to sensitization to the carbohydrate and, subsequently, to red meat allergy.

In 2023, the US Centres for Disease Control and Prevention declared α -gal syndrome a public health concern.² Patients can develop anaphylaxis from unexpected sources of α -gal exposure including vaccines (e.g., live herpes zoster vaccine; measles, mumps and rubella vaccine), supplements (e.g., collagen), medications (e.g., heparin, cetuximab) and heart valve replacements (Box 1).³

3 Diagnosis of α -gal syndrome is challenging, given its spectrum of presentations

Unlike other food allergy reactions to protein antigens, α -gal reactions are delayed and occur up to 8 hours following ingestion of red meat. Symptoms can include urticaria, angioedema and respiratory, gastro-intestinal and cardiovascular manifestations of anaphylaxis.⁴ Some patients have only gastrointestinal symptoms, leading to a misdiagnosis of food intolerance rather than allergy. Diagnosis of α -gal syndrome has increased among patients previously thought to have idiopathic anaphylaxis.⁵

Clinicians should consider α -gal syndrome in the differential diagnosis of unusual food or drug reactions

A new onset of reactions to red meat (an uncommon allergen) should alert clinicians to suspect α -gal syndrome. Diagnosis requires a thorough clinical assessment along with immunoglobulin (Ig) E testing, which is commercially available.

Management is similar to that of other IgE-mediated allergies

Patients with α -gal syndrome should avoid all red meat and α -galcontaining products, but can safely consume white meat and fish. Patients should carry an epinephrine autoinjector and obtain a medical alert bracelet. Immunotherapy to induce desensitization is not yet available.

Box 1: Potential sources of α -gal antigen

Foods

- Red meat (e.g., beef, pork, lamb)
- Animal viscera (e.g., kidney, liver, heart, intestine)
- Sausage casing
- Dairy (e.g., milk, cheese, yogurt, butter)
- Animal-based shortening (e.g., lard, tallow)
- Gelatin-containing snacks (e.g., marshmallows, gummy bears, fruit snacks)

Supplements

Collagen

Vaccines

• Gelatin-containing vaccines (e.g., live herpes zoster; measles, mumps and rubella; yellow fever)

Prescription medicine

- Pancreatic enzyme replacement
- Monoclonal antibodies (e.g., cetuximab)

Medical products

- Gelatin-based colloid plasma substitute (e.g., gelafundin)
- Heparin (sourced from porcine intestine)
- Bovine and porcine heart valves

References

- Nelder MP, Russell CB, Clow KM, et al. Occurrence and distribution of *Ambylomma* americanum as determined by passive surveillance in Ontario, Canada (1999– 2016). *Ticks Tick Borne Dis* 2019;10:146-155.
- Thompson JM, Carpenter A, Kersh GJ, et al. Geographic distribution of suspected alpha-gal syndrome cases: United States, January 2017–December 2022. MMWR Morb Mortal Wkly Rep 2023;72:815-20.
- 3. Platts-Mills TAE, Li R-C, Keshavarz B, et al. Diagnosis and management of patients with the α -gal syndrome. *J Allergy Clin Immunol Pract* 2020;8:15-23.e1.
- Commins SP, Satinover SM, Hosen J, et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol 2009;123:426-33.
- Carter MC, Ruiz-Esteves KN, Workman L, et al. Identification of alpha-gal sensitivity in patients with a diagnosis of idiopathic anaphylaxis. *Allergy* 2018;73:1131-4.

Competing interests: Samira Jeimy reports research funding from the Academic Medical Organization of Southwestern Ontario and Schulich School of Medicine and Dentistry, as well as consulting fees and honoraria from Sanofi, GSK, Miravo, AstraZeneca, Medexus, Stallergenes Greer and Novartis. She is a clinical expert with the Canadian Agency for Drugs and Technologies in Health, vice-chair of the Allergy and Clinical Immunology section of the Ontario Medical Association, chair of the Women in Medicine committee of the Ontario Medical Association, co-chair and planning member of the Canadian Women in Allergy and Clinical Immunology annual conference and founding member of Focused COVID Communications. Rongbo Zhu reports honoraria for lectures from AstraZeneca, GSK, Medexus Pharmaceuticals, Sanofi, StallergenesGreer and ValeoPharma, as well as participation on data safety monitoring boards for Bausch Health and ValeoPharma. No other competing interests were declared.

This article has been peer reviewed.

Affiliation: Division of Clinical Immunology and Allergy, Department of Medicine, Western University, London, Ont.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

Correspondence to: Samira Jeimy, samira.jeimy@lhsc.on.ca

CMAJ invites submissions to "Five things to know about ..." Submit manuscripts online at http://mc.manuscriptcentral.com/cmaj